Pancreatic Cancer Research

ResearcherUniversitätsmedizin GreifswaldActive in the last 2 years

Ujjwal Mukund Mahajan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7238-8775; OpenAlex author ID A5033388868. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 16

  1. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  2. Human multiethnic radiogenomics reveals low-abundancy microRNA signature in plasma-derived extracellular vesicles for early diagnosis and molecular subtyping o… Co-author DOI 10.7554/elife.103737↗
  3. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes. Co-author DOI 10.3892/ijo.2024.5614↗
  4. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  5. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  6. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Co-author DOI 10.3390/cancers14215240↗
  7. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenoc… Co-author DOI 10.1053/j.gastro.2021.05.055↗
  8. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  9. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  10. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13014-020-01624-1↗
  11. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  12. [Pancreatic Cancer in the Year 2018 - Room for Precision Medicine?] Co-author DOI 10.1055/a-0542-4310↗
  13. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2016-312432↗
  14. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311393↗
  15. Development of Pancreatic Cancer: Targets for Early Detection and Treatment. Co-author DOI 10.1159/000445233↗
  16. Multifunctional gold nanorods for selective plasmonic photothermal therapy in pancreatic cancer cells using ultra-short pulse near-infrared laser irradiation. First author DOI 10.1039/c5nr00114e↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia V. Mayerle · 14 shared papers, 2015–2024 · strength 1.34
  2. Georg Beyer · 7 shared papers, 2018–2022 · strength 0.66
  3. Frank Ulrich Weiß · 8 shared papers, 2016–2022 · strength 0.61
  4. Markus M. Lerch · 8 shared papers, 2016–2022 · strength 0.61
  5. Ivonne Regel · 5 shared papers, 2018–2024 · strength 0.55
  6. Elisabetta Goni · 4 shared papers, 2018–2022 · strength 0.34
  7. Roland Rad · 3 shared papers, 2018–2022 · strength 0.27
  8. Robert Grützmann · 3 shared papers, 2018–2022 · strength 0.27
  9. Christian P. Pilarsky · 3 shared papers, 2018–2022 · strength 0.27
  10. Marius Distler · 3 shared papers, 2018–2022 · strength 0.27
  11. Jorg H. Kleeff · 2 shared papers, 2018–2024 · strength 0.25
  12. John P. Neoptolemos · 3 shared papers, 2018–2022 · strength 0.24
  13. Simon Sirtl · 2 shared papers, 2022 · strength 0.24
  14. Yi Zhun Zhu · 1 shared paper, 2025 · strength 0.22
  15. Maciej Pech · 1 shared paper, 2025 · strength 0.22
  16. Wenjie Shi · 1 shared paper, 2025 · strength 0.22
  17. Christoph Kahlert · 1 shared paper, 2025 · strength 0.22
  18. Ulf D. Kahlert · 1 shared paper, 2025 · strength 0.22
  19. Waldemar H. Uhl · 2 shared papers, 2021–2022 · strength 0.21
  20. Fritz Klein · 2 shared papers, 2021–2022 · strength 0.21
  21. Yonggan Xue · 2 shared papers, 2021–2022 · strength 0.21
  22. Kirsten Lauber · 2 shared papers, 2021 · strength 0.19
  23. Simone Benitz · 1 shared paper, 2024 · strength 0.19
  24. Quan Zhou · 1 shared paper, 2024 · strength 0.19
  25. Holger Kalthoff · 2 shared papers, 2018–2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.